VENTURE LIFE GROUP PLC

Report Publication Announcement • Nov 14, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3116W

Venture Life Group PLC

14 November 2017

14 November 2017

Venture Life Group plc

("Venture Life" or "the Group")

Vox Markets

Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, provides an update on its engagement with Vox Markets.

Venture Life encourages shareholder engagement through a variety of channels and has decided to focus some of its investor communications through Vox Markets.

Vox Markets is an information platform, built to compile all financial updates, reports, presentations, directors' commentary, video interviews and podcasts in a compliant environment.  Vox Markets aggregates information onto a non-biased forum which will allow enhanced access for existing shareholders and simultaneously increase the audience by the inclusion of Asset Managers, Stock Brokers, Hedge Fund Managers, Private Investors, Independent Financial Advisors, and Investment Managers which may not be familiar with the Group's potential.

To stay abreast with the latest on Venture Life, interested parties should follow "VLG" at www.voxmarkets.co.uk/company/vlg and download the Vox Markets app www.voxmarkets.co.uk/app to receive push notifications as and when Venture Life feature on a podcast interview, are mentioned in the press, or have an RNS released.

For further information please contact:

Venture Life Group PLC			+44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Walbrook PR	venturelife@walbrookpr.com or + 44 (0) 20 7933 8780
Anna Dunphy / Paul McManus		+44 (0) 7876 741 001 / +44 (0) 7980 541 893

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAEFDFADXFFF